Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 747 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Motility Disorders Clear all

Conditions: Esophageal Motility Disorders
Interventions: Per oral endolumenal myotomy; Procedure
Lead sponsor: The Oregon Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gastroesophageal Reflux Disease
Interventions: SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 62
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more

Conditions: Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
Interventions: Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy, Linaclotide, Plecanatide; Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Scottsdale, Arizona • Philadelphia, Pennsylvania • Madison, Wisconsin

Conditions: Barrett Esophagus, Gastroesophageal Reflux, Esophageal Dysplasia, Esophageal Diseases
Interventions: Not listed
Lead sponsor: CDx Diagnostics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3,173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole ER, Ranitidine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Moline, Illinois

Conditions: Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Functional Vomiting, Irritable Bowel Syndrome (IBS), Constipation, Chronic Intestinal Pseudo-obstruction, Fecal Incontinence, Small Intestinal Bacterial Overgrowth
Interventions: no intervention; Other
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Achalasia
Interventions: POPE; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Gastroesophageal Reflux
Interventions: Vonoprazan; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 7 more

Conditions: Erosive Esophagitis, Reflux Esophagitis, GERD
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Ciliary Dyskinesia
Interventions: Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC), CT of the chest, MRI of the chest; Diagnostic Test
Lead sponsor: ReCode Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastro Esophageal Reflux
Interventions: Esophageal studies; Diagnostic Test
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Progressive Supranuclear Palsy
Interventions: Coenzyme Q10, Placebo; Dietary Supplement · Other
Lead sponsor: Lahey Clinic; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Burlington, Massachusetts

Conditions: Dysphagia, Gastroesophageal Reflux
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration Syndrome, Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), MSA, MSA - Multiple System Atrophy, MSA-C, Multiple System Atrophy, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP)
Interventions: Whole genome sequencing will be performed at the NIH; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Bariatric Surgery, Sleeve Gastrectomy, Gastroesophageal Reflux Disease
Interventions: Modified Vertical Sleeve Gastrectomy (mVSG), Conventional Vertical Sleeve Gastrectomy (cVSG); Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Orange, California • San Diego, California

Conditions: Gastroesophageal Reflux
Interventions: externally applied cricoid cartilage pressure; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 20 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Strabismus
Interventions: Not listed
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 88 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: GERD
Interventions: Gatekeeper Reflux Repari System (Device); Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: Not listed
Enrollment: 55 participants
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Achalasia
Interventions: Endoscopic Myotomy, Endoscopic Myotomy for treatment of achalasia; Procedure
Lead sponsor: The Oregon Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Gastroesophageal Reflux
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Transplant, GERD
Interventions: Reflux Band; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
Interventions: Tributyrin, Placebo; Drug
Lead sponsor: Prabesh Kanel; Other
Eligibility: 45 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Esophageal Motility Disorders, Gastric Motor Dysfunction, Aspiration Pneumonia, Gastro Esophageal Reflux
Interventions: Prucalopride, Famotidine; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 89 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Search by objective public record fields.

Endolumenal Partial Myotomy for Esophageal Motility Disorders

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

GCC Agonist Signal in the Small Intestine

The WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) U.S. Registry

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Indiana University Gastrointestinal Motility Diagnosis Registry

Institutional Outcome Data From Per-oral Plication of the Esophagus

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults

Esophageal and Gastric Registry and Biorepository

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)

Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin

The CurePSP Genetics Program

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

Diagnostic Tests in Supra-Esophageal Gastroesophageal Reflux Disease (SE-GERD)

Mobile Medical Application for Cost-effective Strabismus Screening

Gatekeeper European 005

Endoscopic Myotomy of the Lower Esophageal Sphincter for Achalasia

Barrett's Esophagus Patient Registry

The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Gastrointestinal Dysmotility on Aspiration Risk

Remote Monitoring in Progressive Supranuclear Palsy (PSP)